Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Related Articles by Review for PubMed (Select 15170309)

1.

A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.

Neffe AT, Meyer B.

Angew Chem Int Ed Engl. 2004 May 24;43(22):2937-40. No abstract available.

PMID:
15170309
2.

Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.

Courter JR, Madani N, Sodroski J, Schön A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, LaLonde JM, Smith AB 3rd.

Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Epub 2014 Feb 6. Review.

3.

Virus entry as a target for anti-HIV intervention.

Esté JA.

Curr Med Chem. 2003 Sep;10(17):1617-32. Review.

PMID:
12871111
4.

A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.

Wang HG, Williams RE, Lin PF.

Curr Pharm Des. 2004;10(15):1785-93. Review.

PMID:
15180540
5.

HIV-1 entry inhibitors in the side pocket.

Sodroski JG.

Cell. 1999 Oct 29;99(3):243-6. Review. No abstract available.

6.

Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.

Vermeire K, Schols D.

Expert Opin Investig Drugs. 2005 Oct;14(10):1199-212. Review.

PMID:
16185162
7.

Specific CD4 down-modulating compounds with potent anti-HIV activity.

Vermeire K, Schols D.

J Leukoc Biol. 2003 Nov;74(5):667-75. Epub 2003 Aug 1. Review.

8.

Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.

Kazmierski WM, Kenakin TP, Gudmundsson KS.

Chem Biol Drug Des. 2006 Jan;67(1):13-26. Review.

PMID:
16492145
9.

[Replication inhibitors targeting early events in the HIV-1 life cycle].

Ichiyama K, Yamamoto N.

Nihon Rinsho. 2002 Apr;60(4):784-9. Review. Japanese.

PMID:
11968789
10.

Cosalane and its analogues: a unique class of anti-HIV agents.

Zhan P, Li Z, Liu X.

Mini Rev Med Chem. 2010 Sep;10(10):966-76. Review.

PMID:
20540707
11.

HIV gp120: double lock strategy foils host defences.

Sattentau QJ.

Structure. 1998 Aug 15;6(8):945-9. Review.

PMID:
9739096
12.

Inhibition of HIV-1 entry: multiple keys to close the door.

Hertje M, Zhou M, Dietrich U.

ChemMedChem. 2010 Nov 8;5(11):1825-35. doi: 10.1002/cmdc.201000292. Review. No abstract available.

PMID:
20845361
13.

Inhibition of HIV entry by carbohydrate-binding proteins.

Balzarini J.

Antiviral Res. 2006 Sep;71(2-3):237-47. Epub 2006 Mar 9. Review.

PMID:
16569440
14.

Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.

Flores A, Quesada E.

Curr Med Chem. 2013 Feb 1;20(6):751-71. Review.

PMID:
23278399
15.

HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.

De Clercq E.

Int J Biochem Cell Biol. 2004 Sep;36(9):1800-22. Review.

PMID:
15183346
16.

Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery.

Zhan P, Li W, Chen H, Liu X.

Curr Med Chem. 2010;17(29):3393-409. Review.

PMID:
20712566
17.

HIV-1 gp120 V3 loop for structure-based drug design.

Sirois S, Sing T, Chou KC.

Curr Protein Pept Sci. 2005 Oct;6(5):413-22. Review.

PMID:
16248793
18.

[HIV and glycosylation].

Nakata M, Mizuochi T.

Tanpakushitsu Kakusan Koso. 1998 Dec;43(16 Suppl):2567-73. Review. Japanese. No abstract available.

PMID:
9883688
19.

Bioactive CD4 ligands as pre- and/or postbinding inhibitors of HIV-1.

Briant L, Devaux C.

Adv Pharmacol. 2000;48:373-407. Review. No abstract available.

PMID:
10987097
20.

Redox control on the cell surface: implications for HIV-1 entry.

Matthias LJ, Hogg PJ.

Antioxid Redox Signal. 2003 Feb;5(1):133-8. Review.

PMID:
12626125
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk